PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
-
Published:2021-06-28
Issue:2
Volume:269
Page:933-944
-
ISSN:0340-5354
-
Container-title:Journal of Neurology
-
language:en
-
Short-container-title:J Neurol
Author:
Chisari Clara G., Comi Giancarlo, Filippi Massimo, Paolicelli Damiano, Iaffaldano Pietro, Zaffaroni Mauro, Brescia Morra Vincenzo, Cocco Eleonora, Marfia Girolama Alessandra, Grimaldi Luigi Maria, Inglese Matilde, Bonavita Simona, Lugaresi Alessandra, Salemi Giuseppe, De Luca Giovanna, Cottone Salvatore, Conte Antonella, Sola Patrizia, Aguglia Umberto, Maniscalco Giorgia Teresa, Gasperini Claudio, Ferrò Maria Teresa, Pesci Ilaria, Amato Maria Pia, Rovaris Marco, Solaro Claudio, Lus Giacomo, Maimone Davide, Bergamaschi Roberto, Granella Franco, Di Sapio Alessia, Bertolotto Antonio, Totaro Rocco, Vianello Marika, Cavalla Paola, Bellantonio Paolo, Lepore Vito, Patti FrancescoORCID, Avolio Carlo, Balgera Roberto, Banfi Paola, Bellantonio Paolo, Bramanti Placido, Capone Lorenzo, Cavalletti Guido, Chiveri Luca, Clerici Raffaella, Clerico Marinella, Corea Francesco, Dattola Vincenzo, De Robertis Francesca, Di Battista Giancarlo, Galgani Simonetta, Gatto Maurizia, Grasso Maria Grazia, Russo Lorenzo Lo, Logullo Francesco Ottavio, Mantegazza Renato, Protti Alessandra, Rezzonico Monica, Rottoli Mariarosa, Salvetti Marco, Scarpini Elio, Sinisi Leonardo, Sparaco Maddalena, Spitaleri Daniele, Tassinari Tiziana, Tonietti Simone, Valentino Paola, Valzania Franco, Venturi Simonetta,
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference48 articles.
1. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, Investigators A (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910. https://doi.org/10.1056/NEJMoa044397 2. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, Investigators S (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 292(1–2):28–35. https://doi.org/10.1016/j.jns.2010.02.012 3. Fernandez O, Oreja-Guevara C, Arroyo R, Izquierdo G, Perez JL, Montalban X (2012) Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 259(9):1814–1823. https://doi.org/10.1007/s00415-012-6414-9 4. Prosperini L, Gianni C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C (2012) Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 323(1–2):104–112. https://doi.org/10.1016/j.jns.2012.08.027 5. Baldwin KJ, Hogg JP (2013) Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol 26(3):318–323. https://doi.org/10.1097/WCO.0b013e328360279f
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|